Osimertinib is an irreversible third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with clinical activity against CNS metastasis. The product has been approved for five indications, namely:
1) For adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or after EGFR TKI treatment and have been confirmed to have EGFR T790M mutation;
2) For first-line treatment of NSCLC patients with Ex19del or L858R substitution mutations;
3) For adjuvant treatment of adult patients with NSCLC with EGFR-sensitive mutations after tumor resection;
4) Combined with chemotherapy as first-line treatment for NSCLC patients with EGFR mutations;
5) For the treatment of adult patients with locally advanced unresectable (stage III) non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (Ex19del) or exon 21 (L858R) substitution mutations who have not experienced disease progression after definitive platinum-containing chemoradiotherapy.
